Evidence map›Paper›PMID 41488482›Full record

ArticleFrontiers in cellular and infection microbiology2025

Molecular epidemiology of carbapenem-resistant hypervirulent

Na Wang, Lexiu Deng, Huiying Li, Na Jia, Xiaocui Peng, Jianliang Chang, Jiatong Hao, Jianhua Tang, Chunmei Lei, Bu Wang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Frontiers in microbiology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Na WangMicrobiology Department, The First Affiliated Hospital of Hebei North University, Hebei North University, Zhangjiakou, Hebei, China.
Lexiu DengRespiratory Department, The First Affiliated Hospital of Hebei North University, Hebei North University, Zhangjiakou, Hebei, China.
Huiying LiObstetrics and Gynecology Department, The First Affiliated Hospital of Hebei North University, Hebei North University, Zhangjiakou, Hebei, China.
Na JiaClinical Laboratory, Tianjin Nankai Tianyun Hospital, Tianjin, China.
Xiaocui PengRespiratory Department, The First Affiliated Hospital of Hebei North University, Hebei North University, Zhangjiakou, Hebei, China.
Jianliang ChangRespiratory Department, The First Affiliated Hospital of Hebei North University, Hebei North University, Zhangjiakou, Hebei, China.
Jiatong HaoRespiratory Department, The First Affiliated Hospital of Hebei North University, Hebei North University, Zhangjiakou, Hebei, China.
Jianhua TangDepartment of Pharmacy, The First Affiliated Hospital of Hebei North University, Hebei North University, Zhangjiakou, Hebei, China.
Chunmei LeiMicrobiology Department, The First Affiliated Hospital of Hebei North University, Hebei North University, Zhangjiakou, Hebei, China.
Bu WangRespiratory Department, The First Affiliated Hospital of Hebei North University, Hebei North University, Zhangjiakou, Hebei, China.
Jianhua LiuRespiratory Department, The First Affiliated Hospital of Hebei North University, Hebei North University, Zhangjiakou, Hebei, China.
Wei ZhangCentral Laboratory, The First Affiliated Hospital of Hebei North University, Hebei North University, Zhangjiakou, Hebei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Carbapenem-resistant hypervirulent Methods: A single-center molecular epidemiological analysis was conducted on 81 Carbapenem-resistant Results: ST11 accounted for 96.15% (50/52) of CR-hvKP isolates, with K64 being the predominant capsule type (92.31%, 48/52). Additionally, 98.77% (80/81) of CRKP carried ≥1 virulence gene; 64.2% (52/81) of isolates with all five virulence genes exhibited lethality. Conclusion: China faces a rapid dissemination of ST11 CR-hvKP clones carrying diversified CZA resistance mechanisms. The convergence of hypervirulence and resistance in ST11 lineages-accelerated by invasive procedures and international transmission-demands enhanced genomic surveillance. CZA resistance arises through multiple pathways, necessitating combination therapies and stewardship programs limiting prolonged CZA use. Our findings underscore an urgent need for rapid diagnostics targeting emergent resistance determinants and infection control measures to contain high-risk clones.

Indexed as

Anti-Bacterial AgentsAzabicyclo CompoundsCarbapenem-Resistant EnterobacteriaceaeCarbapenemsCeftazidimeDrug Resistance, Multiple, BacterialKlebsiella InfectionsKlebsiella pneumoniaeAgedAnimalsChinaDrug CombinationsFemaleHumansMaleMicrobial Sensitivity TestsAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsCarbapenemsCeftazidimeDrug CombinationsVirulence Factorscarbapenem-resistant hypervirulent Klebsiella pneumoniaeceftazidime/avibactam resistanceChinamolecular epidemiologyST11 clone

Identifiers

PMID41488482
PMCPMC12757409

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.